Translational Research, UAB Mood Disorders Program, UAB Depression and Suicide Center, Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, SC711 Sparks Center, 1720 7th Avenue South, Birmingham, AL, 35294, USA.
Mol Diagn Ther. 2020 Jun;24(3):279-298. doi: 10.1007/s40291-020-00464-9.
Non-invasive peripheral biomarkers play a significant role in both disease diagnosis and progression. In the past few years, microRNA (miRNA) expression changes in circulating peripheral tissues have been found to be correlative with changes in neuronal tissues from patients with neuropsychiatric disorders. This is a notable quality of a biomolecule to be considered as a biomarker for both prognosis and diagnosis of disease. miRNAs, members of the small non-coding RNA family, have recently gained significant attention due to their ability to epigenetically influence almost every aspect of brain functioning. Empirical evidence suggests that miRNA-associated changes in the brain are often translated into behavioral changes. Current clinical understanding further implicates their role in the management of major psychiatric conditions, including major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ). This review aims to critically evaluate the potential advantages and disadvantages of miRNAs as diagnostic/prognostic biomarkers in psychiatric disorders as well as in treatment response.
非侵入性外周生物标志物在疾病诊断和进展中都具有重要作用。在过去的几年中，人们发现循环外周组织中的 microRNA（miRNA）表达变化与神经精神疾病患者的神经元组织变化相关。这是一种生物分子作为疾病预后和诊断生物标志物的显著特性。miRNAs 是小非编码 RNA 家族的成员，由于它们能够表观遗传地影响大脑功能的几乎各个方面，因此最近引起了人们的极大关注。经验证据表明，大脑中与 miRNA 相关的变化常常转化为行为变化。目前的临床认识进一步表明，它们在管理主要精神疾病，包括重度抑郁症（MDD）、双相情感障碍（BD）和精神分裂症（SZ）方面具有重要作用。本综述旨在批判性地评估 miRNAs 作为精神疾病诊断/预后生物标志物以及治疗反应的优缺点。
